Based on the published literature and the data from completed clinical trials, the meta-analysis method was used to systematically evaluate the efficacy and safety of tenofovir and entecavir in the treatment of patients with chronic hepatitis B (CHB) cirrhosis.
PubMed, Web of Science, Embase, Clinicaltrials.gov, Cochrane library, China Biomedical Literature Service System database, China National Knowledge Infrastructure and Wanfang database were comprehensively searched. The search period was from the establishment date of the database to May 2024. The research data of tenofovir and entecavir in the treatment of patients with CHB cirrhosis were collected. The Cochrane systematic review method was used to screen the literature, evaluate the quality of the included literature, and extract the included characteristic information for meta-analysis. The outcome indicators included the negative conversion rate of hepatitis B virus (HBV)-DNA, the normalization rate of glutamic-pyruvic transaminase (GPT), the cumulative incidence of hepatocellular carcinoma (HCC), the cumulative mortality rate and the changes in estimated glomerular filtration rate (eGFR).
A total of 18 articles were included, involving 13 251 patients. The results showed that at 24 and 48 weeks of treatment, compared with entecavir, the negative conversion rate of HBV-DNA in the tenofovir group[odds ratio (OR)=0.84, 95% confidence interval (CI): 0.65—1.08, P=0.17; OR=0.98, 95%CI: 0.28—3.51, P=0.98] and the normalization rate of GPT (OR=1.12, 95%CI: 0.55—2.28, P=0.76; OR=1.35, 95%CI: 0.77—2.36, P=0.29) basically equivalent; Tenofovir can significantly reduce the incidence of cumulative HCC in patients (OR=0.57, 95%CI: 0.42—0.77, P=0.0003), However, there were no significant differences in cumulative mortality (OR=0.89, 95%CI: 0.44—1.83, P=0.76)and the change of eGFR changes (standardized mean difference: -3.02, 95%CI: -18.46—12.42, P=0.70)between the two groups.
Tenofovir and entecavir are basically equivalent in the treatment of CHB cirrhosis patients in terms of HBV-DNA negative conversion rate, eGPT normalization rate, cumulative mortality rate and renal function damage, while the former can significantly reduce the incidence of HCC in patients.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |